BTIG Research Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock

Glaukos (NYSE:GKOS) had its price target raised by equities research analysts at BTIG Research from $131.00 to $141.00 in a report issued on Thursday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s target price would indicate a potential upside of 0.44% from the company’s current price.

Several other brokerages have also recently commented on GKOS. William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Piper Sandler reiterated an “overweight” rating and set a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Needham & Company LLC boosted their price target on Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Stephens boosted their price target on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.85.

Glaukos Stock Down 2.3%

Shares of GKOS opened at $140.38 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 5.43. Glaukos has a one year low of $73.16 and a one year high of $146.75. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of -42.80 and a beta of 0.94. The stock has a 50 day moving average price of $114.02 and a 200 day moving average price of $107.68.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. During the same period in the previous year, the business earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 41.2% on a year-over-year basis. Equities research analysts forecast that Glaukos will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the sale, the director directly owned 18,806 shares in the company, valued at $2,207,448.28. This represents a 44.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alex R. Thurman sold 2,511 shares of the company’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. The trade was a 5.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 19,657 shares of company stock valued at $2,250,060. 5.80% of the stock is owned by company insiders.

Institutional Trading of Glaukos

Large investors have recently added to or reduced their stakes in the stock. AustralianSuper Pty Ltd grew its holdings in shares of Glaukos by 10.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock worth $36,685,000 after purchasing an additional 43,750 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock worth $54,645,000 after purchasing an additional 27,646 shares during the period. SG Americas Securities LLC grew its holdings in shares of Glaukos by 460.8% during the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock worth $6,801,000 after purchasing an additional 49,492 shares during the period. TD Asset Management Inc purchased a new position in shares of Glaukos during the 3rd quarter worth $1,157,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Glaukos by 32.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after purchasing an additional 87,781 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q1 results and outlook: Glaukos reported a Q1 revenue beat, 41% year-over-year growth, narrower loss and a raised 2026 revenue outlook — the key fundamental catalyst supporting the stock. Zacks: Q1 Earnings Beat & Raised Outlook
• Positive Sentiment: Analyst upgrades: Multiple firms raised ratings/targets after the quarter — BTIG bumped its target to $141 (buy), Wells Fargo to $138 (overweight), JPMorgan to $140 (overweight) and Needham raised its target — these actions validate the quarter’s strength and support further investor interest. BTIG Research PT Raise
• Neutral Sentiment: Analyst target mix: although several firms raised targets and ratings, many new targets are close to the current price, implying limited near-term upside from those specific forecasts. Wells Fargo PT Raise
• Neutral Sentiment: Market reaction nuance: after the after-hours jump, some intraday profit-taking is common when a stock has run up; elevated volume today suggests active repositioning by traders. OCBJ: After-Hours Move
• Negative Sentiment: Some revised price targets are below the current market price (e.g., Needham and others), which can encourage short-term selling or cap upside until guidance and execution confirm sustained growth. Needham PT Update

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.